PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
;
Isabel Dos-Santos-Silva ;
OliviaFletcher;
NicholaJohnson;
Manjeet KBolla;
Elinor JSawyer;
IanTomlinson;
Michael JKerin;
NicolaMiller;
FederikMarme;
BarbaraBurwinkel;
RongxiYang;
PascalGuénel;
ThérèseTruong;
FlorenceMenegaux;
MarieSanchez;
StigBojesen;
Sune FNielsen;
HenrikFlyger;
JavierBenitez;
M PilarZamora;
Jose Ignacio AriasPerez;
PrimitivaMenéndez;
HodaAnton-Culver;
SusanNeuhausen;
ArgyriosZiogas;
Christina AClarke;
HermannBrenner;
VolkerArndt;
ChristaStegmaier;
HiltrudBrauch;
ThomasBrüning;
Yon-DschunKo;
Taru AMuranen;
KristiinaAittomäki;
CarlBlomqvist;
Natalia VBogdanova;
Natalia NAntonenkova;
AnnikaLindblom;
SaraMargolin;
ArtoMannermaa;
VesaKataja;
Veli-MattiKosma;
Jaana MHartikainen;
Amanda BSpurdle;
kConFabInvestigators;
Australian Ovarian Cancer Study Group;
ElsWauters;
DominiekSmeets;
BenoitBeuselinck;
GiuseppeFloris;
JennyChang-Claude;
AnjaRudolph;
PetraSeibold;
DieterFlesch-Janys;
Janet EOlson;
CelineVachon;
Vernon SPankratz;
CatrionaMcLean;
Christopher AHaiman;
Brian EHenderson;
FredrickSchumacher;
LoicLe Marchand;
VesselaKristensen;
Grethe GrenakerAlnæs;
WeiZheng;
David JHunter;
SaraLindstrom;
Susan EHankinson;
PeterKraft;
IreneAndrulis;
Julia AKnight;
GordGlendon;
Anna MarieMulligan;
ArjaJukkola-Vuorinen;
MerviGrip;
SailaKauppila;
PeterDevilee;
Robert AEMTollenaar;
CarolineSeynaeve;
AntoinetteHollestelle;
MontserratGarcia-Closas;
JonineFigueroa;
Stephen JChanock;
JolantaLissowska;
KamilaCzene;
HatefDarabi;
MikaelEriksson;
Diana MEccles;
SajjadRafiq;
William JTapper;
Sue MGerty;
Maartje JHooning;
John WMMartens;
J MargrietCollée;
MadeleineTilanus-Linthorst;
PerHall;
JingmeiLi;
Judith SBrand;
KeithHumphreys;
AngelaCox;
Malcolm WRReed;
CraigLuccarini;
CarolineBaynes;
Alison MDunning;
UteHamann;
DianaTorres;
Hans UlrichUlmer;
ThomasRüdiger;
AnnaJakubowska;
JanLubinski;
KatarzynaJaworska;
KatarzynaDurda;
SusanSlager;
Amanda EToland;
Christine BAmbrosone;
DrakoulisYannoukakos;
AnthonySwerdlow;
AlanAshworth;
NickOrr;
MichaelJones;
AnnaGonzález-Neira;
GuillermoPita;
M RosarioAlonso;
NuriaÁlvarez;
DanielHerrero;
Daniel CTessier;
DanielVincent;
FrancoisBacot;
JacquesSimard;
MartineDumont;
PennySoucy;
RosalindEeles;
KennethMuir;
FredrikWiklund;
HenrikGronberg;
JohannaSchleutker;
Børge GNordestgaard;
MarenWeischer;
Ruth CTravis;
DavidNeal;
Jenny LDonovan;
Freddie CHamdy;
Kay-TeeKhaw;
Janet LStanford;
William JBlot;
StephenThibodeau;
Daniel JSchaid;
Joseph LKelley;
ChristianeMaier;
Adam SKibel;
CezaryCybulski;
LisaCannon-Albright;
KatjaButterbach;
JongPark;
RadkaKaneva;
JyotsnaBatra;
Manuel RTeixeira;
ZsofiaKote-Jarai;
Ali Amin AlOlama;
SaraBenlloch;
Stefan PRenner;
ArndtHartmann;
AlexanderHein;
MatthiasRuebner;
DietherLambrechts;
ElsVan Nieuwenhuysen;
IgnaceVergote;
SandrinaLambretchs;
Jennifer ADoherty;
Mary AnneRossing;
StefanNickels;
UrsulaEilber;
ShanWang-Gohrke;
KunleOdunsi;
Lara ESucheston-Campbell;
GraceFriel;
GalinaLurie;
Jeffrey LKilleen;
Lynne RWilkens;
Marc TGoodman;
IngoRunnebaum;
Peter AHillemanns;
Liisa MPelttari;
RalfButzow;
FrancesmaryModugno;
Robert PEdwards;
Roberta BNess;
Kirsten BMoysich;
Andreasdu Bois;
FlorianHeitz;
PhilippHarter;
StefanKommoss;
Beth YKarlan;
ChristineWalsh;
JennyLester;
AllanJensen;
Susanne KrügerKjaer;
EstridHøgdall;
BernardPeissel;
BernardoBonanni;
LorisBernard;
Ellen LGoode;
Brooke LFridley;
Robert AVierkant;
Julie MCunningham;
Melissa CLarson;
Zachary CFogarty;
Kimberly RKalli;
DongLiang;
Karen HLu;
Michelle ATHildebrandt;
XifengWu;
Douglas ALevine;
FannyDao;
MariaBisogna;
AndrewBerchuck;
Edwin SIversen;
Jeffrey RMarks;
LucyAkushevich;
Daniel WCramer;
JoellenSchildkraut;
Kathryn LTerry;
Elizabeth MPoole;
MeirStampfer;
Shelley STworoger;
Elisa VBandera;
IreneOrlow;
Sara HOlson;
LineBjorge;
Helga BSalvesen;
Anne Mvan Altena;
Katja KHAben;
Lambertus AKiemeney;
Leon FAGMassuger;
TanjaPejovic;
YukieBean;
AngelaBrooks-Wilson;
Linda EKelemen;
Linda SCook;
Nhu DLe;
BohdanGórski;
JacekGronwald;
JanuszMenkiszak;
Claus KHøgdall;
LeneLundvall;
LotteNedergaard;
Svend AageEngelholm;
EdDicks;
JonathanTyrer;
IanCampbell;
IainMcNeish;
JamesPaul;
NadeemSiddiqui;
RosalindGlasspool;
Alice SWhittemore;
Joseph HRothstein;
ValerieMcGuire;
WeivaSieh;
HuiCai;
Xiao-OuShu;
Rachel TTeten;
RebeccaSutphen;
John RMcLaughlin;
Steven ANarod;
Catherine MPhelan;
Alvaro NMonteiro;
DavidFenstermacher;
Hui-YiLin;
Jennifer BPermuth;
Thomas ASellers;
Y AnnChen;
Ya-YuTsai;
ZhihuaChen;
AleksandraGentry-Maharaj;
Simon AGayther;
Susan JRamus;
UshaMenon;
Anna HWu;
Celeste LPearce;
DavidVan Den Berg;
Malcolm CPike;
AgnieszkaDansonka-Mieszkowska;
JoannaPlisiecka-Halasa;
JoannaMoes-Sosnowska;
JolantaKupryjanczyk;
Paul DpPharoah;
HonglinSong;
IngridWinship;
GeorgiaChenevix-Trench;
Graham GGiles;
Sean VTavtigian;
Doug FEaston;
Roger LMilne;
(2016)
PALB2, CHEK2 and ATM rare variants and cancer risk: data from COGS.
Journal of medical genetics, 53 (12).
pp. 800-811.
ISSN 0022-2593
DOI: 10.1136/jmedgenet-2016-103839
BACKGROUND: The rarity of mutations in PALB2, CHEK2 and ATM make it difficult to estimate precisely associated cancer risks. Population-based family studies have provided evidence that at least some of these mutations are associated with breast cancer risk as high as those associated with rare BRCA2 mutations. We aimed to estimate the relative risks associated with specific rare variants in PALB2, CHEK2 and ATM via a multicentre case-control study. METHODS: We genotyped 10 rare mutations using the custom iCOGS array: PALB2 c.1592delT, c.2816T>G and c.3113G>A, CHEK2 c.349A>G, c.538C>T, c.715G>A, c.1036C>T, c.1312G>T, and c.1343T>G and ATM c.7271T>G. We assessed associations with breast cancer risk (42 671 cases and 42 164 controls), as well as prostate (22 301 cases and 22 320 controls) and ovarian (14 542 cases and 23 491 controls) cancer risk, for each variant. RESULTS: For European women, strong evidence of association with breast cancer risk was observed for PALB2 c.1592delT OR 3.44 (95% CI 1.39 to 8.52, p=7.1×10-5), PALB2 c.3113G>A OR 4.21 (95% CI 1.84 to 9.60, p=6.9×10-8) and ATM c.7271T>G OR 11.0 (95% CI 1.42 to 85.7, p=0.0012). We also found evidence of association with breast cancer risk for three variants in CHEK2, c.349A>G OR 2.26 (95% CI 1.29 to 3.95), c.1036C>T OR 5.06 (95% CI 1.09 to 23.5) and c.538C>T OR 1.33 (95% CI 1.05 to 1.67) (p≤0.017). Evidence for prostate cancer risk was observed for CHEK2 c.1343T>G OR 3.03 (95% CI 1.53 to 6.03, p=0.0006) for African men and CHEK2 c.1312G>T OR 2.21 (95% CI 1.06 to 4.63, p=0.030) for European men. No evidence of association with ovarian cancer was found for any of these variants. CONCLUSIONS: This report adds to accumulating evidence that at least some variants in these genes are associated with an increased risk of breast cancer that is clinically important.
-
picture_as_pdf - jmedgenet-2016-103839.pdf
-
subject - Published Version
-
- Available under Creative Commons: NC-ND 3.0
Explore Further
Read more research from the creator(s):
Find work associated with the faculties and division(s):
Find work from this publication:
Find other related resources:
- https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5200636 (OA Location)
- 10.1136/jmedgenet-2016-103839 (DOI)
- 27595995 (PubMed)